share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  2024/10/25 20:03

牛牛AI助理已提取核心訊息

MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy compared to FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result reinforces previous preclinical successes in establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is expanding its development program with additional studies focusing on diabetic neuropathy and PTSD. As part of its broader strategy, MIRA is also exploring government funding opportunities to support the program's advancement.
MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, demonstrated 60% greater efficacy compared to FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain. This result reinforces previous preclinical successes in establishing Ketamir-2's potential as a breakthrough treatment for neuropathic pain.The company is expanding its development program with additional studies focusing on diabetic neuropathy and PTSD. As part of its broader strategy, MIRA is also exploring government funding opportunities to support the program's advancement.
MIRA製藥公司宣佈,其新型口服氟凱他命類似物Ketamir-2在化療引起的神經性疼痛的臨牀前模型中,效能比FDA批准的伽馬氨丁酸提高了60%。這一結果進一步鞏固了之前在臨牀前研究中確立Ketamir-2作爲神經性疼痛突破性治療的潛力。該公司正在擴展其開發計劃,增加針對糖尿病神經病和創傷後應激障礙(PTSD)的額外研究。作爲其更廣泛的策略的一部分,MIRA還在探索政府資助機會,以支持該計劃的推進。
MIRA製藥公司宣佈,其新型口服氟凱他命類似物Ketamir-2在化療引起的神經性疼痛的臨牀前模型中,效能比FDA批准的伽馬氨丁酸提高了60%。這一結果進一步鞏固了之前在臨牀前研究中確立Ketamir-2作爲神經性疼痛突破性治療的潛力。該公司正在擴展其開發計劃,增加針對糖尿病神經病和創傷後應激障礙(PTSD)的額外研究。作爲其更廣泛的策略的一部分,MIRA還在探索政府資助機會,以支持該計劃的推進。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 909

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。